Changmao Biochemical Engineering Company Limited said it expects to report a consolidated net loss attributable to shareholders of between RMB4 million and RMB6 million for the six months ended 30 June 2026. The projected figure marks a sharp improvement from the RMB25.79 million loss recorded in the same period of 2025.
Management attributed the reduced loss to two main factors: 1. Optimised product mix and expanded production capacity in response to market demand, which lifted both revenue and gross profit. 2. Progressive market expansion for products from the phase-II production line of subsidiary Changmao (Dalian) New Material Company Limited, helping to narrow net losses at that unit.
The figures are based on the Group’s unaudited management accounts; full interim results are scheduled for release on 18 August 2026. The company advised shareholders and potential investors to exercise caution when dealing in its shares.